XNAS
Attovia Therapeutics Inc is a clinical stage biotechnology company focused on research and development of therapeutic products in the fields of immune-mediated diseases. Its product pipeline includes ATTO-1310 and ATTO-2306 for immune-dermatology indications and ATTO-1091 for inflammatory diseases, including inflammatory bowel disease (IBD). The company's product candidates are developed using its ATTOBODY biologics platform.
Attovia’s post-IPO quarter was weak, with an **$0.26 EPS miss** and only **$450k** of revenue, underscoring an early-stage biotech still far from commercial scale. With no catalyst beyond IPO-related governance changes, the print is more placeholder than proof of execution.
AI-generated summary — powered by BigEarnings.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-09-02 | Q2 2026 | -4.62 | -4.88 | -5.63% | $450,000 | ❌ Miss | +0.81% | — | — |
Showing last 1 quarters.